19 results on '"Vidriales, María B."'
Search Results
2. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
3. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
4. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
5. Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
6. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation:a EuroFlow study
7. Investigation of Minimal Residual Disease in Acute Myeloid Leukemia by Immunophenotyping
8. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
9. Minimal residual disease monitoring by flow cytometry
10. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML)
11. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification
12. Investigation of Minimal Residual Disease in Acute Myeloid Leukemia by Immunophenotyping
13. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics
14. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia
15. An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).
16. Erratum: Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML)
17. Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies
18. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.
19. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3 -ITD Mutation-Positive Acute Myeloid Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.